iTeos Therapeutics, Inc. financial data

Symbol
ITOS on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
321 Arsenal Street, Bldg 312, Floor 3, Suite 301, Watertown, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.64K % +20.3%
Debt-to-equity 14.6 % -3.81%
Return On Equity -18.2 % -312%
Return On Assets -15.9 % -314%
Operating Margin -414 % -445%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 36.5M shares +2.07%
Common Stock, Shares, Outstanding 36.5M shares +2.06%
Entity Public Float 380M USD -37.6%
Common Stock, Value, Issued 37K USD +2.78%
Weighted Average Number of Shares Outstanding, Basic 39.7M shares +11%
Weighted Average Number of Shares Outstanding, Diluted 39.7M shares +11%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 35M USD -59.3%
Research and Development Expense 130M USD +24.6%
General and Administrative Expense 50.2M USD +6.29%
Operating Income (Loss) -145M USD -122%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -102M USD -284%
Income Tax Expense (Benefit) 5.66M USD +224%
Net Income (Loss) Attributable to Parent -108M USD -281%
Earnings Per Share, Basic -3 USD/shares -275%
Earnings Per Share, Diluted -3 USD/shares -270%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 251M USD +16.1%
Assets, Current 627M USD +1.96%
Property, Plant and Equipment, Net 5.33M USD +109%
Operating Lease, Right-of-Use Asset 5.5M USD +1.35%
Other Assets, Noncurrent 788K USD -2.96%
Assets 752M USD +6.83%
Accounts Payable, Current 11.1M USD +111%
Employee-related Liabilities, Current 5.3M USD
Accrued Liabilities, Current 15.4M USD -27.4%
Liabilities, Current 34.7M USD +15.5%
Operating Lease, Liability, Noncurrent 4.24M USD -4.25%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 88M USD +9.67%
Accumulated Other Comprehensive Income (Loss), Net of Tax -16.6M USD -25.8%
Retained Earnings (Accumulated Deficit) 79.3M USD -57.7%
Stockholders' Equity Attributable to Parent 664M USD +6.47%
Liabilities and Equity 752M USD +6.83%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -32.4M USD -22%
Net Cash Provided by (Used in) Financing Activities 22K USD -96.2%
Net Cash Provided by (Used in) Investing Activities -69.6M USD -120%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 36.5M shares +2.06%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -105M USD -75.9%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 251M USD +16.1%
Deferred Tax Assets, Valuation Allowance 74.4M USD +63.8%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 76.2M USD +61.8%
Operating Lease, Liability 5.52M USD +1.25%
Payments to Acquire Property, Plant, and Equipment 945K USD +694%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -112M USD -184%
Lessee, Operating Lease, Liability, to be Paid 6.06M USD +1.41%
Property, Plant and Equipment, Gross 9.86M USD +52.2%
Operating Lease, Liability, Current 1.28M USD +25.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.47M USD +22.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.5M USD +22.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 542K USD +3.04%
Lessee, Operating Lease, Liability, to be Paid, Year Three 968K USD -16.7%
Deferred Tax Assets, Operating Loss Carryforwards 21.8M USD +63.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 43M USD +9.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 786K USD +17.5%
Operating Lease, Payments 1.42M USD +53.5%
Additional Paid in Capital 601M USD +33.8%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.84M USD +8.74%
Share-based Payment Arrangement, Expense 29.6M USD +21.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%